口服舒洛地特联合缬沙坦治疗原发性慢性肾小球肾炎的临床研究

目的 观察口服舒洛地特联合血管紧张素受体拮抗剂缬沙坦治疗原发性慢性肾小球肾炎的临床效果.方法 选取本院97例原发性慢性肾小球肾炎患者经常规治疗后分成两组,Ⅰ组（联合治疗组）：给予舒洛地特250LSU 2次/天口服＋缬沙坦80mg 1次/天口服;Ⅱ组（缬沙坦组）：给予缬沙坦80mg 1次/天口服.治疗4个月后检测治疗前后24h尿蛋白定量、白蛋白、血浆纤维蛋白原、凝血酶原时间、活化部分凝血酶时间、甘油三酯、总胆固醇、血压、血肌酐、尿素氮、胱抑素C等指标.结果 白蛋白、凝血酶原时间（PT）、活化部分凝血酶时间（APTT）、甘油三酯（TG）、总胆固醇（TC）、血压（SBP）、血肌酐（Cr）、尿素氮（Ur）治疗前后比较差异无统计学意义（P＞0.05）.治疗后24h尿蛋白定量、血浆纤维蛋白原、胱抑素C较治疗前显著下降（P＜0.05）.治疗后联合治疗组较缬沙坦组24h尿蛋白定量、血浆纤维蛋白原、胱抑素C下降更明显（P＜0.01）.结论 采用舒洛地特联合缬沙坦较单独使用缬沙坦对慢性肾小球肾炎的治疗效果更为显著,为原发性慢性肾小球肾炎的治疗提供了新的方向.

The clinical effects of combined use of Sulodexide and valsartan on chronic glomerulonephritis

Objectives To observe the clinical effects of combined use of Sulodexide and valsartan on chronic glomerulonephritis（CGN）.Methods 97 cases of CGN patients in Mianyang Central Hospital were divided into two groups：group Ⅰ （drug combination：Sulodexide 500LSU ＆#183; d-1 and valsartan 80mg ＆#183; d-1）,group Ⅱ（valsartan group：valsartan 80mg ＆#183; d-1.Before and after 4 months of treatment,the detection result including 24-hour urinary protein excretion,Serum albumin,Plasma fibrinogen,prothrombin time,Activated partial thromboplastin time,Triglycerides,Total cholesterol,Serum creatinine,Urea nitrogen,Cystatin C and Blood pressure,were recorded and analyzed.Results To the contrast,in Serum albumin,prothrombin time,Activated partial thromboplastin time,Triglycerides,Total cholesterol,Serum creatinine,Urea nitrogen,Cystatin C and Blood pressure,there were no difference between the before and after 4 months of treatment（P 〉 0.05）.24-hour urinary protein excretion,Plasma fibrinogen and Cystatin C were significantly lower after 4 months of treatment than that before treatment （P 〈 0.05）.Compared with the valsartan group,24-hour urinary protein excretion,Plasma fibrinogen and Cystatin C were significantly lower in drug combination group（P 〈 0.01）.Conclusions Compared with monotherapy,combination of Sulodexide and valsartan can provides better efficacy,which also provides a new direction for the treatment of chronic glomerulonephritis.